Trade RxSight, Inc. - RXST CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
| Spread | 0.14 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Rxsight Inc ESG Risk Ratings
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
| Prev. Close* | 28.3 |
| Open* | 27.45 |
| 1-Year Change* | 128.18% |
| Day's Range* | 26.47 - 27.47 |
| 52 wk Range | 9.78-33.77 |
| Average Volume (10 days) | 436.66K |
| Average Volume (3 months) | 10.02M |
| Market Cap | 1.06B |
| P/E Ratio | -100.00K |
| Shares Outstanding | 35.64M |
| Revenue | 67.00M |
| EPS | -1.94 |
| Dividend (Yield %) | N/A |
| Beta | -100.00K |
| Next Earnings Date | Nov 6, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 21, 2023 | 27.36 | -0.35 | -1.26% | 27.71 | 27.75 | 26.46 |
| Sep 20, 2023 | 28.30 | 0.15 | 0.53% | 28.15 | 28.76 | 27.71 |
| Sep 19, 2023 | 28.33 | 0.77 | 2.79% | 27.56 | 28.77 | 27.48 |
| Sep 18, 2023 | 28.19 | -1.53 | -5.15% | 29.72 | 29.79 | 28.12 |
| Sep 15, 2023 | 29.77 | 0.01 | 0.03% | 29.76 | 29.88 | 29.44 |
| Sep 14, 2023 | 29.62 | 0.06 | 0.20% | 29.56 | 29.64 | 28.77 |
| Sep 13, 2023 | 29.55 | 2.14 | 7.81% | 27.41 | 29.84 | 27.22 |
| Sep 12, 2023 | 27.64 | -1.82 | -6.18% | 29.46 | 29.86 | 27.54 |
| Sep 11, 2023 | 30.12 | 1.08 | 3.72% | 29.04 | 30.39 | 28.82 |
| Sep 8, 2023 | 28.94 | -0.63 | -2.13% | 29.57 | 30.60 | 28.77 |
| Sep 7, 2023 | 29.65 | 0.27 | 0.92% | 29.38 | 30.46 | 28.96 |
| Sep 6, 2023 | 29.45 | 1.23 | 4.36% | 28.22 | 29.48 | 28.22 |
| Sep 5, 2023 | 28.43 | -0.54 | -1.86% | 28.97 | 28.97 | 28.18 |
| Sep 1, 2023 | 29.12 | 0.66 | 2.32% | 28.46 | 29.45 | 28.46 |
| Aug 31, 2023 | 28.93 | 0.94 | 3.36% | 27.99 | 29.23 | 27.99 |
| Aug 30, 2023 | 29.00 | 1.02 | 3.65% | 27.98 | 29.18 | 27.98 |
| Aug 29, 2023 | 28.61 | 0.61 | 2.18% | 28.00 | 28.88 | 27.57 |
| Aug 28, 2023 | 28.18 | -1.28 | -4.34% | 29.46 | 29.79 | 28.08 |
| Aug 25, 2023 | 29.45 | 0.26 | 0.89% | 29.19 | 29.76 | 28.99 |
| Aug 24, 2023 | 29.32 | -1.10 | -3.62% | 30.42 | 30.42 | 29.26 |
RxSight, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Monday, November 6, 2023 | ||
| Time (UTC) 10:59 | Country US
| Event Q3 2023 Rxsight Inc Earnings Release Q3 2023 Rxsight Inc Earnings ReleaseForecast -Previous - |
| Monday, March 4, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q4 2023 Rxsight Inc Earnings Release Q4 2023 Rxsight Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
| Total revenue | 49.005 | 22.593 | 14.678 | 2.241 |
| Revenue | 49.005 | 22.593 | 14.678 | 2.241 |
| Cost of Revenue, Total | 27.677 | 18.076 | 12.973 | 4.06 |
| Gross Profit | 21.328 | 4.517 | 1.705 | -1.819 |
| Total Operating Expense | 112.323 | 75.38 | 50.09 | 48.311 |
| Selling/General/Admin. Expenses, Total | 58.961 | 33.077 | 15.132 | 15.178 |
| Research & Development | 25.657 | 24.202 | 21.819 | 29.42 |
| Depreciation / Amortization | 0.028 | 0.025 | 0.159 | 0.174 |
| Unusual Expense (Income) | 0 | 0.007 | -0.521 | |
| Operating Income | -63.318 | -52.787 | -35.412 | -46.07 |
| Interest Income (Expense), Net Non-Operating | -3.429 | -3.628 | 0.033 | 2.281 |
| Other, Net | 0 | 7.735 | 63.011 | 170.033 |
| Net Income Before Taxes | -66.747 | -48.68 | 27.632 | 126.244 |
| Net Income After Taxes | -66.756 | -48.688 | 27.575 | 126.22 |
| Net Income Before Extra. Items | -66.756 | -48.688 | 27.575 | 126.22 |
| Net Income | -66.756 | -48.688 | 27.575 | 126.22 |
| Total Adjustments to Net Income | 0 | -24.209 | -100.093 | |
| Income Available to Common Excl. Extra. Items | -66.756 | -48.688 | 3.366 | 26.127 |
| Income Available to Common Incl. Extra. Items | -66.756 | -48.688 | 3.366 | 26.127 |
| Diluted Net Income | -66.756 | -48.688 | 3.366 | 26.127 |
| Diluted Weighted Average Shares | 28.2684 | 27.3668 | 26.295 | 26.295 |
| Diluted EPS Excluding Extraordinary Items | -2.36151 | -1.77909 | 0.12801 | 0.99361 |
| Diluted Normalized EPS | -2.36151 | -1.77909 | 0.12827 | 0.9738 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 20.81 | 17.489 | 16.088 | 12.615 | 11.36 |
| Revenue | 20.81 | 17.489 | 16.088 | 12.615 | 11.36 |
| Cost of Revenue, Total | 8.795 | 7.123 | 8.666 | 7.259 | 6.572 |
| Gross Profit | 12.015 | 10.366 | 7.422 | 5.356 | 4.788 |
| Total Operating Expense | 34.797 | 30.586 | 31.078 | 28.573 | 27.152 |
| Selling/General/Admin. Expenses, Total | 18.254 | 16.283 | 15.803 | 15 | 14.469 |
| Research & Development | 7.348 | 7.137 | 6.599 | 6.275 | 6.075 |
| Depreciation / Amortization | 0.038 | 0.043 | 0.01 | 0.039 | 0.036 |
| Operating Income | -13.987 | -13.097 | -14.99 | -15.958 | -15.792 |
| Interest Income (Expense), Net Non-Operating | 0.209 | -0.115 | -0.615 | -0.86 | -0.94 |
| Other, Net | 0 | 0 | 0 | ||
| Net Income Before Taxes | -13.778 | -13.212 | -15.605 | -16.818 | -16.732 |
| Net Income After Taxes | -13.804 | -13.212 | -15.61 | -16.818 | -16.732 |
| Net Income Before Extra. Items | -13.804 | -13.212 | -15.61 | -16.818 | -16.732 |
| Net Income | -13.804 | -13.212 | -15.61 | -16.818 | -16.732 |
| Total Adjustments to Net Income | |||||
| Income Available to Common Excl. Extra. Items | -13.804 | -13.212 | -15.61 | -16.818 | -16.732 |
| Income Available to Common Incl. Extra. Items | -13.804 | -13.212 | -15.61 | -16.818 | -16.732 |
| Diluted Net Income | -13.804 | -13.212 | -15.61 | -16.818 | -16.732 |
| Diluted Weighted Average Shares | 34.4983 | 31.6371 | 30.4196 | 27.6658 | 27.5599 |
| Diluted EPS Excluding Extraordinary Items | -0.40014 | -0.41761 | -0.51316 | -0.6079 | -0.60711 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.39332 | -0.41761 | -0.51316 | -0.6079 | -0.60711 |
| Unusual Expense (Income) | 0.362 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
| Total Current Assets | 134.555 | 176.295 | 81.5 | 90.199 |
| Cash and Short Term Investments | 105.802 | 159.332 | 68.975 | 80.668 |
| Cash & Equivalents | 11.834 | 24.361 | 13.994 | 7.958 |
| Short Term Investments | 93.968 | 134.971 | 54.981 | 72.71 |
| Total Receivables, Net | 10.956 | 4.862 | 2.865 | 0.789 |
| Accounts Receivable - Trade, Net | 10.956 | 4.862 | 2.865 | 0.789 |
| Total Inventory | 14.835 | 8.032 | 8.288 | 7.219 |
| Prepaid Expenses | 2.962 | 4.069 | 1.372 | 1.523 |
| Total Assets | 150.164 | 192.721 | 100.677 | 110.432 |
| Property/Plant/Equipment, Total - Net | 14.081 | 15.501 | 18.606 | 19.25 |
| Property/Plant/Equipment, Total - Gross | 33.979 | 31.846 | 30.979 | 27.789 |
| Accumulated Depreciation, Total | -19.898 | -16.345 | -12.373 | -8.539 |
| Other Long Term Assets, Total | 1.528 | 0.925 | 0.571 | 0.983 |
| Total Current Liabilities | 17.237 | 11.077 | 11.6 | 8.457 |
| Accounts Payable | 2.595 | 1.689 | 1.134 | 2.199 |
| Accrued Expenses | 10.81 | 8.615 | 4.935 | 5.715 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.152 | 0.02 | 0.027 | 0.129 |
| Other Current Liabilities, Total | 3.68 | 0.753 | 5.504 | 0.414 |
| Total Liabilities | 60.262 | 54.479 | 44.906 | 87.462 |
| Total Long Term Debt | 40.212 | 39.777 | 24.436 | 0.054 |
| Long Term Debt | 40.169 | 39.76 | 24.399 | 0 |
| Capital Lease Obligations | 0.043 | 0.017 | 0.037 | 0.054 |
| Other Liabilities, Total | 2.813 | 3.625 | 8.87 | 78.951 |
| Total Equity | 89.902 | 138.242 | 55.771 | 22.97 |
| Redeemable Preferred Stock | 0 | 353.3 | 327.581 | |
| Common Stock | 0.028 | 0.027 | 80.78 | 56.422 |
| Retained Earnings (Accumulated Deficit) | -546.032 | -479.276 | -377.503 | -360.224 |
| Other Equity, Total | -0.095 | -0.02 | -0.806 | -0.809 |
| Total Liabilities & Shareholders’ Equity | 150.164 | 192.721 | 100.677 | 110.432 |
| Total Common Shares Outstanding | 28.2684 | 27.3668 | 26.295 | 26.295 |
| Additional Paid-In Capital | 636.001 | 617.511 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 187.666 | 134.555 | 139.162 | 149.928 | 161.147 |
| Cash and Short Term Investments | 153.939 | 105.802 | 112.835 | 128.62 | 143.847 |
| Cash & Equivalents | 11.012 | 11.834 | 8.912 | 24.004 | 24.132 |
| Short Term Investments | 142.927 | 93.968 | 103.923 | 104.616 | 119.715 |
| Total Receivables, Net | 12.668 | 10.956 | 9.02 | 6.884 | 5.626 |
| Accounts Receivable - Trade, Net | 12.668 | 10.956 | 9.02 | 6.884 | 5.626 |
| Total Inventory | 18.067 | 14.835 | 15.336 | 11.622 | 8.49 |
| Prepaid Expenses | 2.992 | 2.962 | 1.971 | 2.802 | 3.184 |
| Total Assets | 202.532 | 150.164 | 155.706 | 166.714 | 177.062 |
| Property/Plant/Equipment, Total - Net | 13.359 | 14.081 | 14.951 | 15.787 | 14.972 |
| Other Long Term Assets, Total | 1.507 | 1.528 | 1.593 | 0.999 | 0.943 |
| Total Current Liabilities | 14.876 | 17.237 | 16.368 | 12.996 | 10.659 |
| Accounts Payable | 3.717 | 2.595 | 4.172 | 3.277 | 2.587 |
| Accrued Expenses | 11.045 | 14.49 | 12.036 | 9.593 | 7.997 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 0.114 | 0.152 | 0.16 | 0.126 | 0.075 |
| Other Current Liabilities, Total | |||||
| Total Liabilities | 57.523 | 60.262 | 59.747 | 56.728 | 53.899 |
| Total Long Term Debt | 40.309 | 40.212 | 40.099 | 39.988 | 39.974 |
| Long Term Debt | 40.309 | 40.169 | 40.025 | 39.881 | 39.89 |
| Capital Lease Obligations | 0 | 0.043 | 0.074 | 0.107 | 0.084 |
| Other Liabilities, Total | 2.338 | 2.813 | 3.28 | 3.744 | 3.266 |
| Total Equity | 145.009 | 89.902 | 95.959 | 109.986 | 123.163 |
| Redeemable Preferred Stock | |||||
| Common Stock | 0.034 | 0.028 | 0.028 | 0.027 | 0.027 |
| Additional Paid-In Capital | 704.228 | 636.001 | 626.491 | 623.746 | 620.106 |
| Retained Earnings (Accumulated Deficit) | -559.244 | -546.032 | -530.422 | -513.604 | -496.872 |
| Other Equity, Total | -0.009 | -0.095 | -0.138 | -0.183 | -0.098 |
| Total Liabilities & Shareholders’ Equity | 202.532 | 150.164 | 155.706 | 166.714 | 177.062 |
| Total Common Shares Outstanding | 33.9667 | 28.2684 | 27.7191 | 27.6315 | 27.4857 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
| Net income/Starting Line | -66.756 | -48.688 | 27.575 | 126.22 |
| Cash From Operating Activities | -58.85 | -44.708 | -35.203 | -40.619 |
| Cash From Operating Activities | 4.022 | 3.988 | 4.012 | 3.93 |
| Non-Cash Items | 11.296 | 2.67 | -58.942 | -166.798 |
| Cash Taxes Paid | 0.003 | 0.02 | 0.061 | 0.019 |
| Cash Interest Paid | 4.257 | 3.187 | 0.425 | 0.026 |
| Changes in Working Capital | -7.412 | -2.678 | -7.848 | -3.971 |
| Cash From Investing Activities | 39.95 | -81.907 | 15.591 | -5.87 |
| Capital Expenditures | -2.393 | -1.94 | -2.539 | -4.086 |
| Other Investing Cash Flow Items, Total | 42.343 | -79.967 | 18.13 | -1.784 |
| Cash From Financing Activities | 6.332 | 137.342 | 25.237 | 1.33 |
| Financing Cash Flow Items | -1.375 | -0.132 | -0.687 | 0 |
| Issuance (Retirement) of Stock, Net | 7.828 | 122.501 | 1.066 | 1.515 |
| Issuance (Retirement) of Debt, Net | -0.121 | 14.973 | 24.858 | -0.185 |
| Foreign Exchange Effects | -0.009 | -0.01 | 0.005 | |
| Net Change in Cash | -12.577 | 10.717 | 5.625 | -45.154 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -13.212 | -66.756 | -51.146 | -34.328 | -17.596 |
| Cash From Operating Activities | -17.764 | -58.85 | -44.996 | -29.808 | -14.985 |
| Cash From Operating Activities | 0.999 | 4.022 | 3.061 | 2.081 | 1.035 |
| Non-Cash Items | 2.189 | 11.296 | 8.675 | 5.707 | 2.805 |
| Cash Taxes Paid | 0 | 0.003 | 0.003 | 0.003 | 0 |
| Cash Interest Paid | 1.348 | 4.257 | 3.037 | 1.907 | 0.928 |
| Changes in Working Capital | -7.74 | -7.412 | -5.586 | -3.268 | -1.229 |
| Cash From Investing Activities | -48.365 | 39.95 | 29.545 | 28.985 | 14.859 |
| Capital Expenditures | -0.747 | -2.393 | -2.031 | -1.451 | -0.37 |
| Other Investing Cash Flow Items, Total | -47.618 | 42.343 | 31.576 | 30.436 | 15.229 |
| Cash From Financing Activities | 65.305 | 6.332 | 0.025 | 0.48 | -0.098 |
| Financing Cash Flow Items | -0.567 | -1.375 | -1.082 | -0.504 | -0.362 |
| Issuance (Retirement) of Stock, Net | 65.913 | 7.828 | 1.189 | 1.044 | 0.308 |
| Issuance (Retirement) of Debt, Net | -0.041 | -0.121 | -0.082 | -0.06 | -0.044 |
| Foreign Exchange Effects | 0.002 | -0.009 | -0.023 | -0.014 | -0.005 |
| Net Change in Cash | -0.822 | -12.577 | -15.449 | -0.357 | -0.229 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
RxSight, Inc. Company profile
About Rxsight Inc
RxSight, Inc. is a commercial-stage medical technology company. The Company is engaged in improving the vision of patients following cataract surgery. Its RxSight Light Adjustable Lens system (RxSight system), comprised of its RxSight Light Adjustable Lens (LAL), RxSight Light Delivery Device (LDD) and accessories, is the intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. Its LAL is made of photosensitive material that changes shape in response to patterns of ultraviolet (UV) light generated by its LDD. Its RxSight system helps surgeon to performs a standard cataract procedure to implant the LAL, and then uses the LDD to modify the lens with the visual correction needed for the patient’s vision outcomes. Alternative IOL technologies, are not adjustable following the surgery and therefore require patients to make pre-operative choices about their visual preferences.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Rxsight Inc revenues increased 54% to $22.6M. Net loss applicable to common stockholders totaled $48.7M vs. income of $3.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects Change in fair value of warrants decrease of 96% to $2.7M (income), Selling, general and administrative - B increase from $15.1M to $31.2M
| Industry: | Medical Equipment, Supplies & Distribution (NEC) |
100 Columbia Street
Suite 120
ALISO VIEJO
CALIFORNIA 92656
US
Income Statement
- Annual
- Quarterly
News
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com